E Inovio Pharmaceuticals Offers Upside Potential With Its Lead Drug

On September 9, Inovio Pharmaceuticals (INO), provided business updates at the H.C. Wainwright 21st Annual Global Investment Conference. Following the favorable updates, the stock has seen quite some interest, and shares rose by more than 19% in subsequent days. In this article, we intend to review its lead candidate, VGX-3100, alone. The drug has successfully met its efficacy endpoints in mid-stage trials and is now investigating in a Phase 3 REVEAL trial. So, we want to dive into the VGX-3100 data to see if Inovio is a great “Buy” candidate at current levels.

Company description

Inovio Pharmaceuticals is a clinical-stage biotechnology company that concentrates on developing DNA-based immunotherapies and vaccines for the treatment of cancers and infectious diseases. The company, based in Plymouth Meeting, Pennsylvania, was founded in 1979 and went public in December 1998. Inovio Pharmaceuticals is led by J. Joseph Kim who joined the company in 2009 from VGX Pharmaceuticals. Currently, the company has a market cap of ~ $200M and trades around $2.3 per share.

VGX-3100 Overview

In our opinion, the most promising medicine in INO’s pipeline is VGX-3100, a DNA-based immunotherapy designed to increase T cell immune responses against the E6 and E7 antigens of Human Papillomavirus (HPV). The drug is being considered for several indications. Accordingly, VGX-3100 is being studied as a treatment for Cervical High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar HSIL, and Anal HSIL.

Data from the Phase 2 trial of VGX-3100, which was published in the Lancet Journal in September 2015, demonstrated promising results. As we can see below, the drug met its primary endpoint, showing superb efficacy versus a placebo, with a histologic regression observed in 53 out of 107 (49.5%) women treated with VGX-3100. The results were statistically significant to the placebo arm, with a p-value of 0.017. From the safety standpoint, the drug was generally well-tolerated with no unexpected toxicities.

1 2 3 4
View single page >> |

Disclosure: No positions in any stock mentioned

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Ayelet Wolf 9 months ago Member's comment

Any updates on $INO?

Alpha Stockman 1 year ago Member's comment

Good read, but hard to see the images. Can you please fix?